How often are CJC-1295 and Ipamorelin dosed?

Frequency follows half-life

The DAC form of CJC-1295 binds albumin, giving it a 6–8-day half-life (documented in a cited human pharmacokinetic study), which is why it is dosed once weekly. CJC-1295 without DAC (Mod GRF 1-29) and Ipamorelin have short half-lives, so they are dosed several times daily — pre-bed being the most common single-dose timing, aligning with the natural overnight growth-hormone pulse.

The two ways the pair is run

• Standard (no-DAC) pair: CJC-1295 no-DAC and Ipamorelin are co-administered at the same frequency — multiple times daily — because their short half-lives are synchronized.
• DAC alternative: CJC-1295 DAC once weekly, with Ipamorelin still dosed daily — two different schedules, since Ipamorelin's daily pulse adds the pulsatile signal the long-acting CJC-1295 DAC does not.

About the amounts and the combination

This reports frequency, which follows the cited pharmacology. The specific microgram amounts and exact number of daily doses are community convention, not from a controlled trial — the profiles state there are no approved dosing standards for the combination itself. Reported, not a recommendation.

• CJC-1295 with DAC: once weekly (6–8-day half-life).
• CJC-1295 without DAC (Mod GRF 1-29): multiple times daily (short half-life).
• Ipamorelin: multiple times daily, pre-bed most common (short half-life).
• No controlled-trial protocol for the combination; amounts are convention.